CHICAGO, March 22, 2021 / PRNewswire / – NuggMD, the nation's leading medical cannabis telemedicine platform, launches services in Connecticut and in Illinois. The popular platform will now be available in 11 states, including new York, Nevada, Missouri, Pennsylvania, Ohio, California, New Jersey, Virginia, and Oklahoma. NuggMD has connected more than 700,000 patients with their medical marijuana doctors since 2016 and is now available to over 100 million Americans.
Both Connecticut and Illinois have revised their guidelines due to COVID. Governor Lamont March 2020 Executive Order 7L allows residents in Connecticut Receive their medical marijuana assessment via telemedicine for the duration of the COVID emergency. Illinois Residents are also no longer required to receive their medical marijuana reviews in person. State-approved doctors can make recommendations via telemedicine until further notice. Patients in both states can now receive safe and socially distant MMJ telehealth assessments without the risk of unnecessary exposure to disease in a medical setting. This, along with many other safety modifications, makes cannabis access safer for high-risk patients.
"We welcome states that have a compassionate stance on patient safety," said Kam Babazade, co-founder and COO of NuggMD. "The most at-risk cannabis patients no longer have to brave public waiting rooms to get the relief they need. This is a huge step in the right direction in helping everyone stay healthy."
Connecticut Governor Malloy, who signed the legislation, said he had reprioritized law enforcement for violent and more serious crimes. The following year he signed the medical cannabis program. The state is currently actively considering laws that would legalize recreational sales by 2022, but it's not yet certain whether the law has enough support to pass. To qualify for medical marijuana use, a Connecticut Residents must have one of the state's more than 3 dozen qualifying requirements. Some of the most common medical conditions that are approved for medical marijuana treatment in Connecticut Include cancer, PTSD, interstitial cystitis, and chronic pain lasting at least 6 months associated with a specific underlying chronic condition that is unresponsive to other treatment interventions.
In contrast, recreational marijuana has been legalized in Illinois, but the medical marijuana program is still very popular. Registered patients can get discounts in pharmacies and are exempt from paying cannabis excise tax, which can be up to 25%. Registered patients can also purchase more than twice as much cannabis as recreational patients – up to 2.5 ounces – and skip the long recreational lines at double-licensed pharmacies. Patients can also grow up to five plants at home – a privilege not granted to recreational users at all. To qualify Illinois & # 39; Medical Marijuana Program, Patients must have one of 50+ qualifying debilitating conditions for medical marijuana use. Some of the most common conditions on the list are cancer, post-traumatic stress disorder, osteoarthritis, migraines, irritable bowel syndrome, and chronic pain.
NuggMD's fully licensed physicians are available in both states as of 8 a.m. to 10 p.m. every day, even on weekends, without making an appointment. Evaluations in Connecticut are $ 149 and are set at $ 99 in the Illinois. Patients who do not qualify for medical marijuana treatment in their state always receive their assessment for free.
NuggMD is the nation's leading platform for medical marijuana technology, serving patients in California, new York, Nevada, Oklahoma, Missouri, New Jersey, Pennsylvania, Ohio, Virginia, Illinois and now Connecticut. They have personally connected over 700,000 patients to their new medical marijuana doctors through their state-of-the-art telemedicine platform. They believe that everyone has the right to explore the benefits of medicinal cannabis and are determined to help each patient explore all of their options on their path to wellbeing. For more information, visit Nuggmd.com/connecticut and Nuggmd.com/illinois.
Press contact: Renee Cotsis